Background Many drugs are prescribed outside the terms of the marketing authorization (“off-label”). Several studies have shown that this is a common practice in various European healthcare settings. Objective This study aimed to quantify and characterize off-label drug prescribing in children admitted to a Portuguese Paediatric Unit (PEU). Setting This study was conducted in the Paediatric Unit of the university teaching hospital of Cova da Beira Hospital Centre (CHCB), Covilhã, located in the Eastern Central Region of Portugal. Method A descriptive study was conducted, including a sample of 700 children, randomly selected from those admitted between January to October 2010. Drug prescription was assessed by retrospective review of clinical files. Main outcome measure Off-label prescribing was defined as the utilization of a drug at an indication, age, dosage, frequency or route of administration different from those recommended in the Summary of Product Characteristics (SPC). For purposes of this study only the medicines prescribed to be used after discharge from the hospital were studied. Results 364 boys and 336 girls, aged from 4 days to 18 years, were included in this study. Of the 724 medicines prescribed, 32.2 % were off-label. At least one drug was used off-label in 28.1 % of the studied population, corresponding to 46.1 % of the 427 children that received prescriptions. “Alteration in dosage” was the commonest reason for off-label prescribing (28.2 %). The off-label prescriptions comprised mainly drugs acting on the “Respiratory System” and “Anti-infectious agents for systemic use”. Amoxicillin/clavulanic acid, paracetamol, amoxicillin, ibuprofen and salbutamol were the five active principles most frequently prescribed off-label. Conclusion The prevalence of off-label drug prescribing in the Portuguese PEU of CHCB is high, the use in a dose or for an age group not approved in the SPC being the most common reasons for off-label prescription.
Children Off-label prescribing Paediatrics Portugal Prescription
This is a preview of subscription content, log in to check access.
The authors did not receive any financial support for the research, authorship, and/or publication of this article.
Conflicts of interest
Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly. 2006;136(13–14):218–22.PubMedGoogle Scholar
Muhlbauer B, Janhsen K, Pichler J, Schoettler P. Off-label use of prescription drugs in childhood and adolescence: an analysis of prescription patterns in Germany. Dtsch Arztebl Int. 2009;106(3):25–31.PubMedGoogle Scholar
Duarte D. Medicamentos para Crianças A realidade actual na União Europeia. Revista Lusófona de Ciências e Tecnologia da Saúde. 2006;3(1):9–18.Google Scholar
Venitz J, Sittner We. Appropriate dose selection—how to optimize clinical drug development. Vol. 59. Springer; 2007. p. 111–134.Google Scholar
Meadows M. Drug research and children. FDA Consum. 2003;37(1):12–7.Google Scholar
Winterfeld U, Le Heuzey MF, Acquaviva E, Mouren MC, Brion F, Bourdon O. Utilisation hors autorisation de mise sur le marché (AMM) des psychotropes en pédiatrie: une étude prospective. Arch Pediatr. 2009;16(9):1252–60.PubMedCrossRefGoogle Scholar
Strolin Benedetti M, Baltes EL. Drug metabolism and disposition in children. Fundam Clin Pharmacol. 2003;17(3):281–99.PubMedCrossRefGoogle Scholar
Kimland E, Bergman U, Lindemalm S, Bottiger Y. Drug related problems and off-label drug treatment in children as seen at a drug information centre. Eur J Pediatr. 2007;166(6):527–32.PubMedCrossRefGoogle Scholar
Novak E, Allen PJ. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics. Pediatr Nurs. 2007;33(1):64–70.PubMedGoogle Scholar
Autret-Leca E, Bensouda-Grimaldi L, Le Guellec C, Jonville-Béra AP. L’enfant et les médicaments: application à la prescription en pédiatrie. Archives de Pédiatrie. 2005;13:181–5.PubMedCrossRefGoogle Scholar
Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–8.PubMedCrossRefGoogle Scholar
Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544–8.PubMedGoogle Scholar
McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child. 2000;83(6):498–501.PubMedCrossRefGoogle Scholar
Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999;88(9):965–8.PubMedCrossRefGoogle Scholar
Jonville-Bera AP, Bera F, Autret-Leca E. Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study. Eur J Clin Pharmacol. 2005;61(3):231–6.PubMedCrossRefGoogle Scholar
Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000;320(7227):79–82.PubMedCrossRefGoogle Scholar
Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161(3):282–90.PubMedCrossRefGoogle Scholar
Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther. 2009;34(3):277–87.PubMedCrossRefGoogle Scholar
Morales-Carpi C, Estan L, Rubio E, Lurbe E, Morales-Oliva FJ. Drug utilization and off-label drug use among Spanish emergency room paediatric patients. Eur J Clin Pharmacol. 2010;66:315–20.PubMedCrossRefGoogle Scholar
Instituto Nacional de Estatística [on-line]. Available from: http://www.ine.pt. Accessed July 2012.
Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54(6):665–70.PubMedCrossRefGoogle Scholar
Jain SS, Bavdekar SB, Gogtay NJ, Sadawarte PA. Off-label drug use in children. Indian J Pediatr. 2008;75(11):1133–6.PubMedCrossRefGoogle Scholar
Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, et al. Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol. 2005;61(10):775–9.PubMedCrossRefGoogle Scholar
‘t Jong GW, Eland IA, Sturkenboom MC, van den Arker JN, Strickerf BH. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J. 2004;23(2):310–3.PubMedCrossRefGoogle Scholar
Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt KG, Laer S. Off-label drug use among hospitalised children: identifying areas with the highest need for research. Pharm World Sci. 2008;30(5):497–502.PubMedCrossRefGoogle Scholar
‘t Jong G, Eland IA, Strickerf BH, van den Anker JN. Information for paediatric use of medicines in a product information compendium. Paediatr Perinatal Drug Ther. 2001;4(4):148–51.Google Scholar
Smith AR, Barbato A, Beydon N, Bisgaard H, de Boeck K, Brand P, et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J. 2010;35:247–65.CrossRefGoogle Scholar